Literature DB >> 6683005

Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.

C Mattsson, S Nilsson, L Häggroth.   

Abstract

The thrombolytic activity and elimination rate in vivo of a plasminogen activator purified from a melanoma cell line was examined in a rabbit thrombus model. Following an intravenous injection of 125I labelled plasminogen activator, its biological activity disappeared very rapidly from the plasma (t1/2 = 1.5 min) and radioactivity immediately accumulated in the liver. After a two-hour infusion with a total amount of 0.5 mg plasminogen activator a 60 per cent reduction in the weight of partially occluding thrombi was noted. No significant thrombolysis was seen in totally occluded vessels. Treatment with 0.5 mg plasminogen activator caused no depletion of fibrinogen or alpha 2-antiplasmin. No significant thrombolysis occurred after infusion of 0.5 mg streptokinase, but total lysis of occluding and non-occluding thrombi was obtained after a two-hour infusion of 1 mg streptokinase, without any reduction of fibrinogen. A marked reduction of alpha 2-antiplasmin was seen after both 0.5 and 1 mg of streptokinase treatment but were not seen in rabbits infused with plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683005     DOI: 10.1016/0049-3848(83)90400-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Characterization of indium-111 labeled recombinant tissue plasminogen activator for the imaging of thrombi.

Authors:  D J Hnatowich; F Virzi; P W Doherty; J Wilson; J Rosa; J E Ansell
Journal:  Eur J Nucl Med       Date:  1987

Review 2.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

3.  Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis.

Authors:  A S Maizel; J J Bookstein
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

4.  Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment.

Authors:  Adnan I Qureshi; Haitham M Hussein; Mohamed Abdelmoula; Alexandros L Georgiadis; Nazli Janjua
Journal:  Neurocrit Care       Date:  2008-12-03       Impact factor: 3.210

5.  Prolonged Microcatheter-Based Local Thrombolytic Infusion as a Salvage Treatment After Failed Endovascular Treatment for Cerebral Venous Thrombosis: A Multicenter Experience.

Authors:  Adnan I Qureshi; Mikayel Grigoryan; Muhammad A Saleem; Emrah Aytac; Shawn S Wallery; Gustavo J Rodriguez; Muhammad F K Suri
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

6.  Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification.

Authors:  E K Kruithof; W D Schleuning; F Bachmann
Journal:  Biochem J       Date:  1985-03-15       Impact factor: 3.857

7.  The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.

Authors:  P L Penar; C A Greer
Journal:  Yale J Biol Med       Date:  1987 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.